에이닷큐어 A.Cure

A.CURE Introduction 1. Core Technology A.CURE specializes in AI-powered voice biomarker analysis for the early detection and severity prediction of heart failure. Its flagship product, Heart to Voice, offers: - Non-invasive diagnostics: Utilizing voice data to predict heart failure severity in four stages (Normal, Mild, Moderate, Severe) with 90.4% accuracy. - Scalable pipeline: Expanding applications to other conditions such as kidney failure, developmental disorders, and cognitive impairments. - AI innovation: Combining advanced AI models (CNN, Transformer) with clinical data for precise health monitoring. 2. Validation - Clinical trials with 112 patients demonstrated a 90.4% accuracy rate in detecting heart failure using AI voice analysis. - Patents filed in 157 countries for proprietary AI voice biomarker technology. - Recognized with the "Paul Dudley White International Scholar Award" at the World Congress of Cardiology 2023. 3. Team Members - CEO: Kyungho Jung Formerly with Aimmed and Hanmi Science, bringing expertise in healthcare innovation and business leadership. - CMO: Eungjoo Kim, M.D. Head of Cardiology at Korea University Guro Hospital, specializing in heart failure diagnosis and treatment. - AI Advisor: Hansuk Kyo, Ph.D. Professor at Korea University and Director of the Intelligent Systems Lab, leading AI development. - Legal Counsel: Sunghwan Oh Overseeing corporate legal affairs and compliance. Company Overview Founded in June 2024, A.CURE is committed to revolutionizing healthcare through accessible AI-driven diagnostic solutions while building partnerships with global medical institutions and technology leaders.